Affiliation:
1. All authors are affiliated with the Medytox, Ochang-eup, Cheongwon-gun, Chungcheongbuk-do, Republic of Korea
Abstract
BACKGROUND
Botulinum toxin (BoNT) has evolved as a popular treatment for various medical and aesthetic conditions since the 1980s. The emergence of new liquid formulation BoNT products in the industry highlights the need to evaluate the value and advantages of these modern formulations.
OBJECTIVE
The aim of this review was to assess and compare the expected difference in practice between liquid and powder formulation BoNT products.
PAITENTS AND METHODS/MATERIALS
This article involves a review of pertinent guidelines, product information from manufacturers, available database for safety reports, and survey results.
RESULTS
Guidelines and safety reports have pointed out potential risks in the reconstitution process, while medication preparation steps are simplified in liquid formulation.
CONCLUSION
The shift toward ready-to-use liquid products can mitigate risks related with reconstitution errors and potentially enhancing patient care by saving time and cost associated with medication preparation.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference5 articles.
1. Formulation composition of botulinum toxins in clinical use;Pickett;J Drugs Dermatol,2010
2. The story of Clostridium botulinum: from food poisoning to Botox;Ting;Clin Med,2004
3. Application of freezing and freeze-drying in pharmaceutical formulation;Izutsu;Adv Exp Med Biol,2018
4. A cautionary Note: botulinum toxin for cervical dystonia reconstituted in sterile water: more pain, still gain;Bart;Mov Disord Clin Pract,2021
5. Incorrect reconstitution of incobotulinum toxin leads to less neurotoxin;Wayne;J Drug Dermatol,2014